The efficacy evaluation of tocilizumab to glucocorticoid-resistant patients with adult Still's disease and systemic juvenile idiopathic arthritis: the open trial The efficacy evaluation of tocilizumabto glucocorticoid-resistant patients with adult Still's diseas ...
The efficacy evaluation of tocilizumab to glucocorticoid-resistant patients with adult Still's disease and systemic juvenile idiopathic arthritis: the open trial - Efficacy assessment of tocilizumab to steroid-resistant patients with adult Still's disease The efficacy evaluation of tocilizumabto glucocorticoid-resistant patients with adult Still's diseas ...
Adult Still's disease and systemic juvenile idiopathic arthritis
Tocilizumab is to be infused every 2 to 4 weeks at 8 mg/kg of body weight
Division of Rheumatology & Clinical Immunology, Jichi Medical University
Study on the glucocorticoid-sparing effects of tocilizumab among glucocorticoid-dependent patients with adult Still's disease and systemic juvenile idiopathic arthritis: the open trial Study on the glucocorticoid-sparing effects of tocilizumabamong glucocorticoid-dependent patients wi ...
Study on the glucocorticoid-sparing effects of tocilizumab among glucocorticoid-dependent patients with adult Still's disease and systemic juvenile idiopathic arthritis: the open trial - Effects of tocilizumab-addition to steroid-dependent patients with adult Still's disease Study on the glucocorticoid-sparing effects of tocilizumabamong glucocorticoid-dependent patients wi ...
Adult Still's disease or systemic juvenile idiopathic arthritis
Tocilizumab (8 mg/kg of body weight) is to be infused every 2 to 4 weeks.
Division of Rheumatology & Clinical Immunology, Jichi Medical University